Whalerock Point Partners’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Whalerock Point Partners’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-60,000	Closed	-$16K	–	149
2019 Q2	$16K	Buy	60,000 +9,000	+18%	+$2.4K	0.01%	145
2019 Q1	$14K	Buy	51,000 +11,000	+28%	+$3.02K	0.01%	128
2018 Q4	$8K	Hold	40,000	–	–	0.01%	94
2018 Q3	$8K	Buy	40,000 +10,000	+33%	+$2K	0.01%	116
2018 Q2	$8K	Hold	30,000	–	–	0.01%	118
2018 Q1	$8K	Buy	30,000 +10,000	+50%	+$2.67K	﹤0.01%	196
2017 Q4	$5K	Hold	20,000	–	–	﹤0.01%	191
2017 Q3	$4K	Buy	+20,000	New	+$4K	﹤0.01%	166
2017 Q2	–	Sell	-20,000	Closed	-$5K	–	174
2017 Q1	$5K	Buy	+20,000	New	+$5K	﹤0.01%	151
2016 Q4	–	Sell	-15,000	Closed	-$8K	–	159
2016 Q3	$8K	Buy	+15,000	New	+$6.86K	﹤0.01%	142

Other funds holding NWBO

WJWM

Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Whalerock Point Partners's NWBO Position: Q3 2019 in Review

Whalerock Point Partners sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2019, closing a stake of 60,000 shares — an estimated $16K sold.

Whalerock Point Partners first reported a position in NWBO in Q3 2016 and held it in 10 quarters. The position peaked at $16K in Q2 2019. 5 funds tracked by Wall St. Rank hold NWBO as of Q3 2019.

Whalerock Point Partners reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2019 after selling out during the quarter.
Whalerock Point Partners sold 60,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2019, an estimated $16K.
Whalerock Point Partners first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2016 and held it in 10 quarters.
Whalerock Point Partners's Northwest Biotherapeutics, Inc. Common stock position peaked at $16K in Q2 2019.
5 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2019.

Based on Whalerock Point Partners's 13F filing for Q3 2019, filed 12 Nov 2019.